SREBF1 and fatty liver disease: Recent studies have shown that miR-103 and miR-107 reduced obesogenic diet-induced hepatic steatosis via decreasing the protein expression of SREBP1 in resveratrol-treated rats [49], and pseudoprotodioscin promoted cholesterol effluxion through targeting SREBP1c and SREBP2 mediated by miR-33a/b in an in vitro experiment [48].